王海001 问03月31日...

王海001 问

03月31日 15:34

▲

公司在干细胞药物的布局非常多，但是迟迟无法推进到临床试验。特别是，从mesoblast引进的两个产品什么时候可以进入临床试验？是否存在无法克服的技术障碍？
The company has a lot of stem cell drugs, but it has not been able to advance to clinical trials. In particular, when will the two products introduced from mesoblast enter clinical trials? Are there technical barriers that cannot be overcome?

天士力 答

03月31日 15:34

▲

感谢您的关注。公司于 2021 年 12 月投资设立全资子公司天士力干细胞产业平台有限公司。公司布局了异体来源的脂肪间充质干细胞治疗亚急性期脑卒中项目，基于组织损伤信号重建理论，通过补充外源性干细胞以保障损伤组织的修复原料供给，促进自体修复能力，实现组织再生与器官功能恢复，目前该项目已经启动正式的临床前研究
Thank you for your attention. The company invested in the establishment of a wholly-owned subsidiary, Tasly Stem Cell Industry Platform Co., Ltd., in December 2021. The company has deployed allogeneic-derived adipose-derived mesenchymal stem cells for the treatment of subacute stroke. Based on the theory of tissue damage signal reconstruction, exogenous stem cells are supplemented to ensure the supply of repair materials for damaged tissue, promote self-repair ability, and achieve tissue regeneration and Organ function recovery, the project has started formal preclinical research